Evaluating Avidity Biosciences: Insights From 10 Financial Analysts
Portfolio Pulse from Benzinga Insights
Avidity Biosciences (NASDAQ:RNA) received mixed ratings from 10 analysts, with a majority being somewhat bullish. The average 12-month price target increased to $71.5, indicating a positive outlook. Despite this, the company faces financial challenges, including a decline in revenue growth and low profitability metrics.
October 21, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Avidity Biosciences has received a mix of bullish and somewhat bullish ratings from analysts, with an average price target increase to $71.5. Despite positive analyst sentiment, the company faces financial challenges, including a decline in revenue growth and low profitability metrics.
The mixed analyst ratings, with a majority being somewhat bullish, suggest a neutral short-term impact on the stock price. The increase in the average price target to $71.5 indicates a positive outlook, but the company's financial challenges, such as declining revenue and low profitability, may offset this optimism. Therefore, the overall short-term impact is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100